Candid Therapeutics licensed a trispecific T-cell engager from WuXi Biologics today for autoimmune disease. Chairman & CEO Ken Song talks about T-cell engagers vs CAR-Ts for autoimmune

blonca9
Jan 6
1 min read

He describes two clinical programs that Candid currently has targeting BCMA and CD20. Plus, discovery programs with U.S. and China based antibody shops, as well as today's deal.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Candid Therapeutics licensed a trispecific T-cell engager from WuXi Biologics today for autoimmune disease. Chairman & CEO Ken Song talks about T-cell engagers vs CAR-Ts for autoimmune

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight